Azithromycin suppresses human osteoclast formation and activity in vitro

Area of Science:

• Oral Biology
• Pharmacology
• Immunology

Background:

• Periodontitis is an inflammatory condition characterized by alveolar bone resorption.
• Azithromycin, an antibiotic, possesses anti-inflammatory properties and is used as an adjunct therapy for periodontitis.

Purpose of the Study:

• To investigate the in vitro effects of azithromycin on human osteoclast formation and resorptive activity.
• To elucidate the molecular mechanisms underlying azithromycin's impact on osteoclasts.

Main Methods:

• Osteoclasts were generated from human peripheral blood mononuclear cells stimulated with M-CSF and RANKL.
• Azithromycin's effects were assessed on osteoclast formation, resorptive activity, gene expression (NFATc1, TRAF6, Cathepsin K, Integrin β3, MMP-9), and actin ring formation.
• Osteoclast function was evaluated at various concentrations of azithromycin (0.5–40 µg/ml).

Main Results:

• Azithromycin significantly reduced osteoclast resorptive activity across all tested concentrations.
• Higher azithromycin concentrations (20 and 40 µg/ml) significantly inhibited osteoclast formation.
• Azithromycin decreased mRNA and protein expression of NFATc1, TRAF6, Cathepsin K, Integrin β3, and MMP-9, and inhibited actin ring formation.

Conclusions:

• Azithromycin effectively inhibits human osteoclast formation and resorptive activity in vitro.
• The observed inhibition of osteoclast function by azithromycin provides a potential explanation for its therapeutic benefits in periodontitis treatment.
• Azithromycin's anti-osteoclastogenic effects may contribute to mitigating alveolar bone loss in periodontitis.